Definitions
from The American Heritage® Dictionary of the English Language, 5th Edition.
- noun A broad-spectrum cephalosporin antibiotic, C22H22N6O7S2, that is given intravenously and is especially effective against some species of Pseudomonas.
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A third-generation
cephalosporin antibiotic , usually reserved for the treatment ofinfections caused by Pseudomonas aeruginosa.
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- noun a parenteral cephalosporin (trade names Fortaz and Tazicef) used to treat moderate infections
Etymologies
from The American Heritage® Dictionary of the English Language, 4th Edition
Support
Help support Wordnik (and make this page ad-free) by adopting the word ceftazidime.
Examples
-
TP: Strains showing combined resistance to ceftazidime (MIC, 16 µg/ml), imipenem (MIC, 16 µg/ml), and meropenem (MIC, 16 µg/ml) were routinely screened for MβL genes by standards PCRs (2, 9, 11).
Behe's Test, Take 2 2008
-
Strains showing combined resistance to ceftazidime (MIC, 16 µg/ml), imipenem (MIC, 16 µg/ml), and meropenem (MIC, 16 µg/ml) were routinely screened for MβL genes by standards PCRs (2, 9, 11).
Behe's Test, Take 2 2008
-
While antibiotics such as ceftazidime are currently used, gram- negative bacteria are becoming increasingly resistant to available options, Srinivasan said.
unknown title 2011
-
And with the first time negotiation in North America for the combination of ceftazidime and NXL 104.
Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011
-
So our anti-infective product portfolio antibiotics with our active predominantly against both gram-positive pathogens, like ceftaroline and ceftaroline NXL 104 and also products active against gram-negative pathogens like ceftazidime and with NXL 104, addressing virtually the entire spectrum of clinical relevant bacterial pathogens.
Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011
-
And just a quick follow-up, Marco, did you mention that we should expect the Phase II data for the NXL 104/ceftazidime combination this quarter?
Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011
-
In the coming months, we expect report the topline result from to and going to Phase II clinical trial for ceftazidime 104, in patients with complicated intra-abdominal infection, and in patients with complicated urinary tract infection.
Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011
-
In this transaction with AstraZeneca, which was executed immediately following AstraZeneca acquisition of Novexel, we acquired additional rights to NXL 104, covering not only the combination with ceftaroline but also adding U.S. right to the combination of ceftazidime and NXL 104, as well as other future possible combination with other antibiotics.
Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011
-
Since late 2008, we have added six major active installments towards the 2012 pipeline expansion goal, including Daxas, levomilnacipran, LAS 977 and ceftazidime/104, and we have advanced aclidinium and linaclotide through Phase III, and cariprazine through proof-of-concept to full Phase III development.
Forest Laboratories Q3 2011 Earnings Call Transcript - Seeking Alpha 2011
-
Excluding the $229 million one-time charge taken in the just completed quarter in connection with the previously announced agreement with AstraZeneca to acquire additional rights to NXL104 and ceftazidime/104, as described in the earnings release, earnings totaled $0.83 per share.
Healthcare Sector and Stocks Analysis from Seeking Alpha 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.